Fitbit Inc (NYSE:FIT) is up 6% in pre-market trading this morning following Christmas Day’s news that its app made it to the top of the free app category in Apple’s app store. The app remains the most downloaded app in the health and fitness category for the entire month of December. According to TipRanks’ statistics, out of the 11 analysts who have rated the company in the past 3 months, 9 gave a Buy rating while 2 remain on the sidelines. The average 12-month price target for the stock is $48.20, marking a 67% upside from where shares last closed.

FIT Consensus

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is falling close to 7% in pre-market trading this morning after the company announced that CEO Michael Pearson will be on medical leave due to pneumonia. The company confirmed reports that Pearson was hospitalized last week for his condition. In his absence, the Board of Directors appointed a committee to oversee the CEO’s responsibilities. According to TipRanks’ statistics, out of the 22 analyst who have rated the company in the last 3 months, 13 gave a Buy rating, 1 gave a Sell rating, while 8 remain on the sidelines. The average 12-month price target for the stock is $164.06,marking a 44% upside from where shares last closed.

VRX Consensus

Chimerix Inc (NASDAQ:CMRX) is plunging 77% in pre-market trading this morning following today’s announcement that its antiviral drug brincidofovir failed to achieve the primary endpoint of its Phase 3 trial. The drug was intended to prevent CMV infection (clinically significant cytomegalovirus) in patients undergoing HTC (hematopoietic cell transplantation), used to treat patients with certain blood and bone marrow cancers. According to TipRanks’ statistics, out of the 6 analysts who have rated CMRX in the last 3 months, 5 gave a Buy rating while 1 remains on the sidelines. The average 12-month price target for the stock is $58.67, marking a 65% upside from where shares last closed.

CMRX Consensus

pSivida Corp. (NASDAQ:PSDV) is up over 4% in pre-market trading to $4.55 after the biotech company announced this morning that it plans to file for EU marketing approval for Medidur, a drug intended to treat posterior uveitis. The company is basing its application on a single Phase 3 clinical trial due the high statistical significance of the results. According to TipRanks, both analysts who have weighed in on the stock are bullish with an average 12-month price target of $11.25, marking a 157% potential upside from where shares last closed.

PSDV Consensus